Panacea Acquisition Stock Quote NUVB - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.74

Bid

Ask

Volume

8,955,051

1.69 Day's Range 1.82

1.54 52 Week Range 3.97

Market Cap

592.058M

Previous Close

1.81

Open

1.815

Last Trade

999

1.74

(formt)

Last Trade Time

Financial Volume

$ 15,627,645

VWAP

1.7451

Average Volume (3m)

4,337,324

Shares Outstanding

340,262,976

Dividend Yield

PE Ratio

-1.03

Earnings Per Share (EPS)

-1.67

Revenue

7.87M

Net Profit

-567.94M

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ecor1cap.com

Headquarters

Wilmington, Delaware, USA

Founded

Panacea Acquisition Corp is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NUVB. The last closing price for Panacea Acquisition was $1.81. Over the last year, Panacea Acquisition shares have traded in a share price range of $ 1.54 to $ 3.97.

Panacea Acquisition currently has 340,262,976 shares outstanding. The market capitalization of Panacea Acquisition is $615.88 million. Panacea Acquisition has a price to earnings ratio (PE ratio) of -1.03.

Overall Flow

Bullish

Net Premium

49k

Calls / Puts

200.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Form 8-K - Current report

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable...

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

Presentation will highlight the comparable efficacy and safety of taletrectinib across pivotal studies and different ethnicities and world...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.79	-31.2252964427	2.53	2.72	1.72	11565517	2.15310012	CS
4	-0.5	-22.3214285714	2.24	2.72	1.72	6746191	2.2114857	CS
12	-0.18	-9.375	1.92	2.72	1.54	4337324	2.10508953	CS
26	-0.88	-33.5877862595	2.62	3.455	1.54	3418278	2.22690177	CS
52	-1.18	-40.4109589041	2.92	3.97	1.54	2591243	2.44052837	CS
156	-1.64	-48.5207100592	3.38	4.31	0.95	1471291	2.34516513	CS
260	-8.26	-82.6	10	15.23	0.95	1288882	3.68087386	CS

NUVB - Frequently Asked Questions (FAQ)

What is the current Panacea Acquisition share price?

The current share price of Panacea Acquisition is $ 1.74

How many Panacea Acquisition shares are in issue?

Panacea Acquisition has 340,262,976 shares in issue

What is the market cap of Panacea Acquisition?

The market capitalisation of Panacea Acquisition is USD 615.88M

What is the 1 year trading range for Panacea Acquisition share price?

Panacea Acquisition has traded in the range of $ 1.54 to $ 3.97 during the past year

What is the PE ratio of Panacea Acquisition?

The price to earnings ratio of Panacea Acquisition is -1.03

What is the cash to sales ratio of Panacea Acquisition?

The cash to sales ratio of Panacea Acquisition is 74.46

What is the reporting currency for Panacea Acquisition?

Panacea Acquisition reports financial results in USD

What is the latest annual turnover for Panacea Acquisition?

The latest annual turnover of Panacea Acquisition is USD 7.87M

What is the latest annual profit for Panacea Acquisition?

The latest annual profit of Panacea Acquisition is USD -567.94M

What is the registered address of Panacea Acquisition?

The registered address for Panacea Acquisition is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Panacea Acquisition website address?

The website address for Panacea Acquisition is ecor1cap.com

Which industry sector does Panacea Acquisition operate in?

Panacea Acquisition operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CRCLCircle Internet Group Inc	$ 133.80 (25.59%)	34.01M
NINENine Energy Service Inc	$ 0.7366 (25.02%)	56.22M
NYCAmerican Strategic Investment Co	$ 10.50 (12.99%)	1.61k
CNFCNFinance Holdings Limited	$ 0.4919 (12.28%)	57.31k
SSLSasol Ltd	$ 5.44 (12.16%)	3.38M
TGEGeneration Essentials Group	$ 7.3614 (-22.18%)	356.46k
SUPSuperior Industries International	$ 0.33 (-21.93%)	1.79M
XINXinyuan Real Estate Co Ltd	$ 2.02 (-18.88%)	15.77k
ACHRArcher Aviation Inc	$ 9.9899 (-14.83%)	111.01M
PROPros Holding Inc	$ 15.74 (-13.04%)	2.17M
ACHRArcher Aviation Inc	$ 9.9899 (-14.83%)	111.01M
BBAIBigBear ai Holdings Inc	$ 3.715 (-3.00%)	95.9M
FFord Motor Company	$ 10.44 (-0.85%)	90.11M
BTEBaytex Energy Corporation	$ 2.09 (3.98%)	73.32M
RIGTransocean Ltd	$ 3.315 (3.27%)	66.55M